Entera Bio (NASDAQ:ENTX) Stock Crosses Above 50-Day Moving Average – Time to Sell?

Entera Bio Ltd. (NASDAQ:ENTX)’s stock price crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $2.89 and traded as high as $3.13. Entera Bio shares last traded at $3.06, with a volume of 203,524 shares traded.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Lifesci Capital assumed coverage on Entera Bio in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price target on the stock. Leerink Partners began coverage on Entera Bio in a research note on Friday, September 18th. They issued an “outperform” rating and a $9.00 price objective for the company. Guggenheim began coverage on Entera Bio in a report on Thursday, September 24th. They set a “buy” rating and a $11.00 target price for the company. UBS Group set a $9.00 target price on Entera Bio in a research report on Friday, September 18th. Finally, Cantor Fitzgerald began coverage on shares of Entera Bio in a report on Tuesday, September 22nd. They issued an “overweight” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Entera Bio has a consensus rating of “Moderate Buy” and an average price target of $9.60.

Entera Bio Price Performance

The business has a fifty day simple moving average of $2.90 and a 200 day simple moving average of $1.90. The firm has a market cap of $542.63 million, a price-to-earnings ratio of -8.91 and a beta of 1.40.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). On average, research analysts anticipate that Entera Bio Ltd. will post -0.40 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Entera Bio

An institutional investor recently raised its stake in Entera Bio stock. Seven Fleet Capital Management LP increased its holdings in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 51.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 205,542 shares of the company’s stock after acquiring an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned about 0.42% of Entera Bio worth $228,000 at the end of the most recent reporting period. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.